Compare Duke Energy Corp (DUK) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

Duke Energy (DUK) trades at $116.65, up 1.0% today, with a bullish technical signal and consistent earnings beats. The stock shows strong fundamentals with a 15.78% net income margin and a dividend yield supported by recent $1.09 payouts. Revenue growth is steady, reaching $32.24B in 2025, while analyst consensus targets $134.44, implying upside potential.

The outlook is positive due to earnings momentum and data center demand, but risks include rising Treasury yields pressuring utility stocks and high debt levels. Investors should weigh the reliable dividend against interest rate sensitivity and capital expenditure needs for growth initiatives.

INO trades at $1.15, down 0.43% on the day, with a bearish technical signal from moving averages and oscillators. The company shows consistent quarterly earnings beats but operates at significant losses with a -130,000% net income margin and negative cash flow. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with analyst consensus leaning bullish at a $2.75 price target.

The investment case hinges on FDA approval of INO-3107, offering substantial upside from current levels. However, persistent cash burn, minimal revenue, and high valuation multiples relative to sales pose significant risks. Investors face binary outcomes driven by regulatory decisions and commercialization execution.